this isn't a stock, it's a trio of walnut shells, next week is the end of Q, peg sales are already known by the insiders, likely setting up to steamroll any bump up, director sale is likely insider helmet on a stick, if you're going to try and beat these guys make sure you only have lose change in your pocket
no one knows. brand new board, so dividends might never come. the company has 15m on hand. they'll probably have more like 25m on hand in a week when the Q3 is out. however, PEG royalties are way down--- wait and see.
ADSU was just upgraded to a $2 price target by Everest Stock Market Research, add this one to your watch lists immediately we could see huge gains tomorrow morning. The last alert they put a price target on went up over 3000% same day!
Unknown Gem with Brutal Upside Potential ...GLTA
2 Big Drugs already under review by FDA another 1 NDA filing for "Best in Class" Potency Drug and 1 ANDA filing for CHF will follow within 6 months .
NDA submission for our anti-migraine VersaFilm(TM) product had been accepted for review, with an FDA-assigned PDUFA date of February 3, 2014.
(According to Merck's most recent annual report, sales of Maxalt(R) were $638 million in 2012.)
IntelGenx Announces Submission of ANDA for Buprenorphine/Naloxone Sublingual Film Product for the Treatment of Opiate Addiction
(According to IMS Health, U.S. retail sales of Suboxone(R) Sublingual Film were approximately $1.5 billion in 2012.)
Only 20 M on the float ..IGXT has the Potential to hit $10++ within 2 Year ! GLTA
Market Cap : $27 M
Cash: $3 M
Burn-Rate : $2 M a year
Shares Out : 51 M ( 30 M shares are held by Investors )
IGXT´s Monster Pipeline :
Product ......Application......... Status of Development
INT0004/2006 Antidepressant -- US launch in 4Q 2012
INT0008/2007 Migraine -- PDUFA Date on Feb 3 2014
INT0007/2006 Erectile Dysfunction -- NDA filing lin early 2014
INT0001/2004 CHF (Coronary Heart Failure), Hypertension -- ANDA filing in early 2014
INT0027/2011 Undisclosed Partnered with Par Pharma -- ANDA under review by FDA
INT0020/2010 Insomnia -- in Pivotal Study
INT0024/2010 Idiopathic pulmonary fibrosis -- in Pivotal Study
INT0028/2011 Cancer pain (cannabinoid) --in Pivotal Study
INT0030/2011 Animal health -- in Pivotal Study
INT0031/2012 Benign prostatic hyperplasia --in Pivotal Study
sure. I sold some of mine in the 1.70's and added to my Idix and thrx positions. this company is impossible to trust. also, did you see Merck's 3Q PEG sales-- down 30+%-- that doesn't bode well for the future dividends (that, by the way, were promised by the old board-- so who knows what's going to happen now with a brand new 3-member board.) I'm not selling out bc i'm curious to see how this stock plays out and it's just so low right now. I want to sell it-- most poorly managed company over the last 4 yrs-- I've never seen worse management of capital and IP.
HOLD YOUR SHARES........................UNLESS YOU NEED MONEY TO EAT. I WILL NOT SELL A SINGLE SHARE. HOLDING ONM TO 104756 SHARES AT $4.88
A director sells 50K shares late last week and then someone buys almost 400K shares in one pop at the close on Friday. What the heck is going on?
This is what Schwab tells me:
"Third Quarter Earnings Announcement Expected: Earnings will tentatively be announced Wednesday."
I have not looked at my account for a couple days so this could have been posted on Monday. In all likelihood ENZN will push once or twice before the call actually happens. Just like last time.
Good luck everyone!
enzn is the worst investment i've ever made.... this could be a total scam company. I'd just hold if you own any. If not, I wouldn't buy. Buy THRX instead.